Association between the histological subtype of lung adenocarcinoma, EGFR/KRAS mutation status and the ALK rearrangement according to the novel IASLC/ATS/ERS classification
- PMID: 27073516
- PMCID: PMC4812186
- DOI: 10.3892/ol.2016.4233
Association between the histological subtype of lung adenocarcinoma, EGFR/KRAS mutation status and the ALK rearrangement according to the novel IASLC/ATS/ERS classification
Abstract
The present study aimed to investigate the association between epidermal growth factor receptor (EGFR)/Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations, anaplastic lymphoma receptor tyrosine kinase (ALK) rearrangements and the morphological characteristics of lung adenocarcinoma (LAC), according to the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society (IASLC/ATS/ERS) classification in a large group of patients with primary LAC. A total of 200 patients with invasive LAC who had undergone complete resections at the Beijing Chest Hospital (Beijing, China) were randomly selected. The morphology of the samples was reassessed in 5% increments by two pathologists, according to the IASLC/ATS/ERS scheme. EGFR and KRAS mutations were tested by direct DNA sequencing. ALK rearrangements were screened by immunohistochemistry on a Benchmark XT stainer. The data revealed that EGFR and KRAS mutations, and ALK rearrangements were identified in 46.0% (92/200), 9.0% (18/200) and 11.5% (23/200) of the patients, respectively. The EGFR/KRAS mutations and ALK rearrangements were mostly exclusive. However, 1 patient exhibited the coexistence of the EGFR (at exon 20) and KRAS (codon 12) mutations, and another patient exhibited the coexistence of the EGFR mutation (at exon 21) and the ALK gene fusion. EGFR mutations were indicated to be closely associated with the acinar predominant (43/77; 55.8%; P=0.030) and papillary predominant (26/49; 53.1%; P=0.006) subtypes. KRAS mutations were more commonly associated with the solid predominant subtype (9/52; 17.3%; P=0.023) and invasive mucinous LAC (5/10; 50.0%; P=0.004), and less commonly associated with the acinar predominant subtype (1/77; 1.3%; P=0.002). ALK rearrangements more commonly occurred in the solid predominant subtype compared with other subtypes (13/52; 25%; P=0.002), and less commonly occurred in the papillary predominant subtype (1/49; 2.0%; P=0.004). Tumors harboring ALK rearrangements were characterized by signet-ring cell (7/9; 77.8%; P<0.0001) and cribriform (7/12; 58.3%; P<0.0001) patterns. The association between the mutation status and histological subtype in LAC was distinct. The predominant subtype according to the IASLC/ATS/ERS classification provided important information for gene mutations and integrated clinical findings to improve the treatment of LAC patients.
Keywords: International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society; histological subtype; lung adenocarcinoma; mutation status.
Figures

Similar articles
-
Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil.Oncology. 2015;89(3):175-86. doi: 10.1159/000376552. Epub 2015 Apr 1. Oncology. 2015. PMID: 25833149
-
Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients.J Thorac Oncol. 2013 Jan;8(1):52-61. doi: 10.1097/JTO.0b013e3182769aa8. J Thorac Oncol. 2013. PMID: 23242438
-
[Relevance of molecular alterations in histopathologic subtyping of lung adenocarcinoma based on 2011 International Multidisciplinary Lung Adenocarcinoma Classification].Zhonghua Bing Li Xue Za Zhi. 2012 Aug;41(8):505-10. doi: 10.3760/cma.j.issn.0529-5807.2012.08.001. Zhonghua Bing Li Xue Za Zhi. 2012. PMID: 23157740 Chinese.
-
Association between the novel classification of lung adenocarcinoma subtypes and EGFR/KRAS mutation status: A systematic literature review and pooled-data analysis.Eur J Surg Oncol. 2019 May;45(5):870-876. doi: 10.1016/j.ejso.2019.02.006. Epub 2019 Feb 16. Eur J Surg Oncol. 2019. PMID: 30833014
-
New pathologic classification of lung cancer: relevance for clinical practice and clinical trials.J Clin Oncol. 2013 Mar 10;31(8):992-1001. doi: 10.1200/JCO.2012.46.9270. Epub 2013 Feb 11. J Clin Oncol. 2013. PMID: 23401443 Review.
Cited by
-
[Advances in the Study of Invasive Non-mucinous Adenocarcinoma with Different Pathological Subtypes].Zhongguo Fei Ai Za Zhi. 2023 Jan 20;26(1):22-30. doi: 10.3779/j.issn.1009-3419.2022.102.51. Zhongguo Fei Ai Za Zhi. 2023. PMID: 36792077 Free PMC article. Review. Chinese.
-
Epidermal growth factor receptor (EGFR), KRAS, and BRAF mutations in lung adenocarcinomas: A study from India.Curr Probl Cancer. 2019 Oct;43(5):391-401. doi: 10.1016/j.currproblcancer.2018.12.003. Epub 2018 Dec 17. Curr Probl Cancer. 2019. PMID: 30591192 Free PMC article.
-
Molecular Pathology of Lung Cancer.Cold Spring Harb Perspect Med. 2022 Mar 1;12(3):a037812. doi: 10.1101/cshperspect.a037812. Cold Spring Harb Perspect Med. 2022. PMID: 34751163 Free PMC article. Review.
-
Correlation of TTF-1 immunoexpression and EGFR mutation spectrum in non-small cell lung carcinoma.J Pathol Transl Med. 2021 Jul;55(4):279-288. doi: 10.4132/jptm.2021.05.10. Epub 2021 Jul 8. J Pathol Transl Med. 2021. PMID: 34233113 Free PMC article.
-
Spatial whole exome sequencing reveals the genetic features of highly-aggressive components in lung adenocarcinoma.Neoplasia. 2024 Aug;54:101013. doi: 10.1016/j.neo.2024.101013. Epub 2024 Jun 7. Neoplasia. 2024. PMID: 38850835 Free PMC article.
References
-
- Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N, Manegold C. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol. 2009;27:1227–1234. doi: 10.1200/JCO.2007.14.5466. - DOI - PubMed
-
- Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, et al. West Japan Oncology Group: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol. 2010;11:121–128. doi: 10.1016/S1470-2045(09)70364-X. - DOI - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous